Hutchison China Cancer Trial Shows Clinically Meaningful Benefits
LONDON (Alliance News) - Biopharmaceutical company Hutchison China MediTech Ltd said Monday patients in its FRESCO Phase III study "demonstrated a statistically significant and clinically at Read More